Protagonist Q4 2021 Earnings Report
Key Takeaways
Protagonist Therapeutics reported its fourth quarter financial results and provided a corporate update, highlighting the advancement of rusfertide into a Phase 3 registrational study, completion of enrollment for PN-943 Phase 2 study, and progression of PN-235 into a Phase 2b study by Janssen.
Rusfertide is moving into a Phase 3 registrational study for polycythemia vera.
Enrollment is complete for PN-943 Phase 2 proof-of-concept study in ulcerative colitis.
Janssen is progressing PN-235 into a Phase 2b study in plaque psoriasis.
The company anticipates topline data readout from the Phase 2 IDEAL study of PN-943 in ulcerative colitis in the second quarter of this year.
Protagonist
Protagonist
Forward Guidance
Protagonist Therapeutics plans to continue to demonstrate strength of execution across all current and emerging assets in its pipeline, thereby maximizing the opportunities ahead for substantial value creation this year.